ILMN

SEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 6

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 438,599

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F7 · price: Weighted average sale price representing 1,600 shares sold ranging from $246.80 to $247.64 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 5

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,199

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F6 · price: Weighted average sale price representing 702 shares sold ranging from $245.75 to $246.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 4

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,901

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F5 · price: Weighted average sale price representing 2,400 shares sold ranging from $244.43 to $245.30 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 3

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 443,301

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F4 · price: Weighted average sale price representing 1,300 shares sold ranging from $243.25 to $244.16 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 2

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 444,601

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F3 · price: Weighted average sale price representing 4,600 shares sold ranging from $242.11 to $243.07 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 1

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,201

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F2 · price: Weighted average sale price representing 3,698 shares sold ranging from $241.08 to $242.06 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-19-012999 · form4.xml · nonDerivative · entry 1

Hampton Malcolm Garret · CIK 0001698265 · SVP Clinical Genomics Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,416

SEC source: 0001127602-18-001580 · form4.xml · derivative · entry 2

Hoyt Aimee L · CIK 0001727683 · SVP, Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,625

Underlying: Common Stock · 4,625 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-18-001580 · form4.xml · nonDerivative · entry 1

Hoyt Aimee L · CIK 0001727683 · SVP, Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,542

F1 · shares: Grant of restricted stock units with 25% of the shares subject to the award vesting on each of the first, second, third and fourth anniversaries of the date of grant, subject to the awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-18-001576 · form4.xml · nonDerivative · entry 1

SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,431

SEC source: 0001127602-18-001208 · form4.xml · nonDerivative · entry 1

Dadswell Charles · CIK 0001575229 · Sr VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,411

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

SEC source: 0001127602-18-000910 · form4.xml · nonDerivative · entry 2

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,899

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F3 · price: Weighted average sale price representing 10,537 shares sold ranging from $223.40 to $224.37 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-18-000910 · form4.xml · nonDerivative · entry 1

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 463,436

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F2 · price: Weighted average sale price representing 9,463 shares sold ranging from $222.37 to $223.35 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-18-000283 · form4.xml · derivative · entry 3

EPSTEIN ROBERT S · CIK 0001252004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 1,000 shares

Expires 2022-11-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

SEC source: 0001127602-18-000283 · form4.xml · nonDerivative · entry 2

EPSTEIN ROBERT S · CIK 0001252004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,588

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

SEC source: 0001127602-18-000283 · form4.xml · nonDerivative · entry 1

EPSTEIN ROBERT S · CIK 0001252004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

SEC source: 0001127602-17-035393 · form4.xml · nonDerivative · entry 3

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 472,899

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F4 · price: Weighted average sale price representing 2,977 shares sold ranging from $216.67 to $217.45 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-035393 · form4.xml · nonDerivative · entry 2

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,876

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F3 · price: Weighted average sale price representing 4,600 shares sold ranging from $215.62 to $216.59 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-035393 · form4.xml · nonDerivative · entry 1

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 480,476

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F2 · price: Weighted average sale price representing 12,423 shares sold ranging from $214.55 to $215.36 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-035196 · form4.xml · nonDerivative · entry 1

deSouza Francis A · CIK 0001520943 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,532

SEC source: 0001127602-17-034612 · form4.xml · nonDerivative · entry 1

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 492,899

F1 · shares: Grant of restricted stock units shall vest as follows: 100% of the shares subject to the award shall vest on December 11, 2018, subject to awardee's continuing status as a service provider on such date.

SEC source: 0001127602-17-034610 · form4.xml · derivative · entry 2

Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,306

Underlying: Common Stock · 6,306 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034610 · form4.xml · nonDerivative · entry 1

Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,775

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034606 · form4.xml · derivative · entry 2

SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,379

Underlying: Common Stock · 4,379 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034606 · form4.xml · nonDerivative · entry 1

SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,669

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034604 · form4.xml · derivative · entry 2

Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,006

Underlying: Common Stock · 7,006 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034604 · form4.xml · nonDerivative · entry 1

Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,110

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034602 · form4.xml · derivative · entry 1

MCGINNIS KAREN K · CIK 0001188264 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 935

Underlying: Common Stock · 935 shares

Expires 2021-01-03

F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F1 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034600 · form4.xml · derivative · entry 2

Dadswell Charles · CIK 0001575229 · Sr VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,503

Underlying: Common Stock · 3,503 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034600 · form4.xml · nonDerivative · entry 1

Dadswell Charles · CIK 0001575229 · Sr VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,556

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034598 · form4.xml · derivative · entry 2

OSTADAN OMEAD · CIK 0001642678 · EVP Ops, Products, Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,758

Underlying: Common Stock · 8,758 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034598 · form4.xml · nonDerivative · entry 1

OSTADAN OMEAD · CIK 0001642678 · EVP Ops, Products, Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,207

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034596 · form4.xml · derivative · entry 2

Hampton Malcolm Garret · CIK 0001698265 · EVP Clinical Genomics Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,758

Underlying: Common Stock · 8,758 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034596 · form4.xml · nonDerivative · entry 1

Hampton Malcolm Garret · CIK 0001698265 · EVP Clinical Genomics Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,453

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034594 · form4.xml · derivative · entry 2

Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,758

Underlying: Common Stock · 8,758 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034594 · form4.xml · nonDerivative · entry 1

Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,315

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034592 · form4.xml · derivative · entry 2

deSouza Francis A · CIK 0001520943 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,521

Underlying: Common Stock · 24,521 shares

Expires 2021-01-03

F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.

SEC source: 0001127602-17-034592 · form4.xml · nonDerivative · entry 1

deSouza Francis A · CIK 0001520943 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,470

F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

SEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 7

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 483,558

SEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 6

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 491,717

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F7 · price: Weighted average sale price representing 200 shares sold ranging from $215.62 to $215.67 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 5

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 491,917

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F6 · price: Weighted average sale price representing 1,300 shares sold ranging from $214.52 to $215.29 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 4

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 493,217

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F5 · price: Weighted average sale price representing 4,700 shares sold ranging from $213.50 to $214.48 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 3

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,917

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F4 · price: Weighted average sale price representing 4,769 shares sold ranging from $212.45 to $213.34 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 2

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 502,686

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F3 · price: Weighted average sale price representing 3,294 shares sold ranging from $211.37 to $212.29 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 1

FLATLEY JAY T · CIK 0001189130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 505,980

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F2 · price: Weighted average sale price representing 5,737 shares sold ranging from $210.37 to $211.36 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034089 · form4.xml · nonDerivative · entry 8

Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,395

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F6 · price: Weighted average sale price representing 200 shares sold ranging from $225.06 to $225.21 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034089 · form4.xml · nonDerivative · entry 7

Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,595

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F5 · price: Weighted average sale price representing 200 shares sold ranging from $224.03 to $224.27 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034089 · form4.xml · nonDerivative · entry 6

Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,795

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

SEC source: 0001127602-17-034089 · form4.xml · nonDerivative · entry 5

Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,895

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F4 · price: Weighted average sale price representing 400 shares sold ranging from $219.82 to $220.26 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

SEC source: 0001127602-17-034089 · form4.xml · nonDerivative · entry 4

Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,295

F1 · shares: The sale was made pursuant to a 10b5-1 plan.

F3 · price: Weighted average sale price representing 700 shares sold ranging from $218.51 to $219.49 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.